Literature DB >> 7195662

Comparison of myotoxic effects of lidocaine with epinephrine in rats and humans.

J A Yagiela, P W Benoit, R D Buoncristiani, M P Peters, N F Fort.   

Abstract

Myotoxic effects of 2% lidocaine with 1:100,000 epinephrine were evaluated in rats and humans. Sprague-Dawley rats were give injections in the left gastrocnemius muscle of 0.5 ml of the lidocaine preparation or a control vehicle; they were killed in groups of four at 0, 8, 24, and 48 hours. Blood samples were taken for serum enzyme determinations, and muscle specimens were removed and processed for histologic evaluation. In eight patients undergoing radical neck dissection, 1.8 ml of lidocaine with epinephrine or its control was injected into the sternocleidomastoid muscle approximately 18 hours before surgery. Patients' muscle specimens obtained at surgery were handled similarly to those of the rat. Serum creatine kinase, aspartate aminotransferase, and alanine aminotransferase activities were markedly elevated in the rat at 8 hours in the experimental group, but not in the control group. Histologically, control injections elicited no damage in the rat other than a mild inflammatory reaction along the presumptive needle track. Lidocaine with epinephrine, however, destroyed most of the muscle in which it was injected. Myonecrosis was qualitatively similar in humans. The rat provides a good model for the study of local anesthetic-induced myonecrosis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7195662

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  14 in total

Review 1.  Local anesthetics.

Authors:  J A Yagiela
Journal:  Anesth Prog       Date:  1991 Jul-Oct

2.  [Development of a soft tissue ulcer after long-term peridural infusion].

Authors:  I Balga; H Gerber; C Konrad; J Diebold
Journal:  Anaesthesist       Date:  2009-02       Impact factor: 1.041

3.  Drug action of benzocaine on the sarcoplasmic reticulum Ca-ATPase from fast-twitch skeletal muscle.

Authors:  D Di Croce; P W Trinks; M B Grifo; D Takara; G A Sánchez
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-07-15       Impact factor: 3.000

4.  Rotator cuff healing after continuous subacromial bupivacaine infusion: an in vivo rabbit study.

Authors:  Nicole A Friel; Vincent M Wang; Mark A Slabaugh; FanChia Wang; Susan Chubinskaya; Brian J Cole
Journal:  J Shoulder Elbow Surg       Date:  2012-07-20       Impact factor: 3.019

Review 5.  Adverse effects and drug interactions associated with local and regional anaesthesia.

Authors:  M Naguib; M M Magboul; A H Samarkandi; M Attia
Journal:  Drug Saf       Date:  1998-04       Impact factor: 5.606

6.  Multivesicular liposomal bupivacaine at the sciatic nerve.

Authors:  J Brian McAlvin; Robert F Padera; Sahadev A Shankarappa; Gally Reznor; Albert H Kwon; Homer H Chiang; Jason Yang; Daniel S Kohane
Journal:  Biomaterials       Date:  2014-03-06       Impact factor: 12.479

7.  Bupivacaine crystal deposits after long-term epidural infusion.

Authors:  I Balga; H Gerber; X H Schorno; F Aebersold Keller; H-P Oehen
Journal:  Anaesthesist       Date:  2013-05-15       Impact factor: 1.041

8.  Amide-type local anesthetics action on the sarcoplasmic reticulum Ca-ATPase from fast-twitch skeletal muscle.

Authors:  D E Di Croce; P W Trinks; C de La Cal; G A Sánchez; D Takara
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-06-20       Impact factor: 3.000

9.  Human skeletal muscle biopsy procedures using the modified Bergström technique.

Authors:  R Andrew Shanely; Kevin A Zwetsloot; N Travis Triplett; Mary Pat Meaney; Gerard E Farris; David C Nieman
Journal:  J Vis Exp       Date:  2014-09-10       Impact factor: 1.355

10.  Perineural administration of dexmedetomidine in combination with bupivacaine enhances sensory and motor blockade in sciatic nerve block without inducing neurotoxicity in rat.

Authors:  Chad M Brummett; Mary A Norat; John M Palmisano; Ralph Lydic
Journal:  Anesthesiology       Date:  2008-09       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.